Key Development
Novartis has suffered a significant late-stage pipeline setback after pelacarsen failed to meet the primary endpoint in the Phase III Lp(a)HORIZON cardiovascular outcomes trial. Although treatment reduced lipoprotein(a), or Lp(a), levels, it did not deliver a statistically significant reduction in major cardiovascular events versus placebo among patients with established cardiovascular disease receiving guideline-directed therapy.
The result carries unusual strategic weight because Lp(a)HORIZON was not simply testing whether a drug could lower a biomarker. With more than 8,300 participants, the study was designed to answer the commercially critical question of whether lowering genetically determined Lp(a) could translate into fewer cardiovascular deaths, myocardial infarctions, strokes and urgent coronary revascularizations.
The market reaction reflected those expectations. Novartis shares fell more than 3%, while analysts had previously estimated potential peak annual sales for pelacarsen of approximately $3–6 billion.
Why It Matters
- The Lp(a) hypothesis now faces a higher clinical bar. Elevated Lp(a) is an inherited cardiovascular risk factor affecting roughly one in five people globally, with no approved therapy specifically targeting it. Pelacarsen’s inability to convert biomarker reduction into cardiovascular benefit increases scrutiny of the entire therapeutic class.
- Amgen and Eli Lilly are now under greater pressure. Their respective late-stage Lp(a) programs, olpasiran and lepodisiran, could potentially differentiate through deeper Lp(a) suppression, molecular modality or patient selection—but investors will increasingly demand outcomes data rather than biomarker efficacy alone.
- Novartis’ growth transition becomes more dependent on other pipeline assets. Entresto is already experiencing substantial generic erosion: first-half 2026 sales fell 48% at constant currencies, while rapidly growing products such as Leqvio are being asked to absorb part of the revenue gap.
- Capital allocation scrutiny could increase. Investor attention now shifts toward del-desiran and other late-stage programs acquired through Novartis’ approximately $12 billion acquisition of Avidity Biosciences.
Healthcare Insight Analysis
Pelacarsen illustrates one of the central risks in cardiovascular drug development: biological validation does not automatically equal clinical validation.
Lp(a) remains strongly associated with cardiovascular risk, but the Lp(a)HORIZON result suggests that simply reducing circulating Lp(a) may not be sufficient—or that magnitude of reduction, patient selection, timing of intervention and residual cardiovascular risk could determine whether that biological effect produces measurable clinical benefit.
This distinction matters commercially. The cardiovascular market increasingly rewards therapies that demonstrate hard outcomes, not merely favorable laboratory parameters. As standards of care improve through intensive lipid lowering, antihypertensive therapy and metabolic interventions, experimental agents must demonstrate incremental benefits on top of increasingly effective background treatment.
For Novartis, the setback is therefore less about losing one asset than about reducing the margin for error across the rest of its late-stage portfolio. The company still has powerful growth engines, including Kisqali, Kesimpta, Pluvicto, Scemblix and Leqvio, but the rapid decline of Entresto increases the strategic importance of successful pipeline conversion.
Market Implications
The immediate consequence could be a reassessment of valuations across the Lp(a) ecosystem. Programs delivering deeper and more durable target suppression may retain substantial value, but partnership terms, licensing discussions and biotech financing are likely to become increasingly dependent on evidence that distinguishes biomarker activity from cardiovascular outcomes.
For large pharmaceutical companies, the message is broader: in cardiovascular medicine, the commercial premium belongs to therapies that prove event reduction—not simply target engagement.
The upcoming detailed Lp(a)HORIZON dataset will therefore matter beyond Novartis. It could influence trial design, patient enrichment strategies and investment decisions across the next generation of Lp(a)-targeted medicines.
Source: https://www.reuters.com/legal/litigation/novartis-shares-down-failed-cholesterol-drug-study-increases-pipeline-pressure-2026-09-07/